Oculis Holding AG (OCS) stock
OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW
$7.64+0.14 (+1.87%)
Close on Nov 13, 2026Market cap $459.08MP/E –Yield –
Oculis EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -1.89 CHF. The highest annual figure on record is -1.89 CHF in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1.89 CHF | – |
| FY2024 | Dec 31, 2024 | -2.12 CHF | – |
| FY2023 | Dec 31, 2023 | -2.97 CHF | – |
| FY2022 | Dec 31, 2022 | -11.32 CHF | – |
| FY2021 | Dec 31, 2021 | -5.84 CHF | – |
| FY2020 | Dec 31, 2020 | -5.77 CHF | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -0.16 CHF | – |
| Q2 FY2025 | Jun 30, 2025 | -0.49 CHF | – |
| Q2 FY2024 | Jun 30, 2024 | -0.51 CHF | – |
| Q2 FY2023 | Jun 30, 2023 | -0.38 CHF | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?